1/13
08:03 am
ngne
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Medium
Report
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
1/12
08:55 am
ngne
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome [Yahoo! Finance]
Medium
Report
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome [Yahoo! Finance]
1/12
07:00 am
ngne
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Medium
Report
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
1/5
07:30 am
ngne
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
High
Report
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/4
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13
08:11 am
ngne
Neurogene (NASDAQ:NGNE) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.
High
Report
Neurogene (NASDAQ:NGNE) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.
11/12
04:27 pm
ngne
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome [Yahoo! Finance]
High
Report
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome [Yahoo! Finance]
11/12
04:01 pm
ngne
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
High
Report
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
11/6
08:18 am
ngne
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
Low
Report
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
11/6
07:30 am
ngne
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Medium
Report
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
11/5
04:01 pm
ngne
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/31
07:19 am
ngne
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright.